At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
PDC-1421 Capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating PDC-1421 Capsule and placebo for Major Depressive Disorder. Completed, enrolled 72 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesTaiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionMar 2019
Study CompletionMar 2019
TodayJul 2026
First PostedMar 24, 2015
Enrollment StartApr 10, 2015
Primary CompletionMar 12, 2019
Study CompletionMar 18, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.3 years ago
Interventions
PDC-1421 Capsuledrug
PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
placebodrug
Placebo contained corn starch.